Friday, 12 June 2020

Global Electronic Pill Market Set For Big Growth - Foresight By 2023

Market Scenario
Electronic pills are equipped with sensors and cameras which allow capturing of several images of the gastrointestinal tract. They are used for diagnostic purposes and are increasingly replacing traditional diagnostic methods. It further monitors various parameters such as temperature, conductivity, pH, and dissolved oxygen. Market Research Future (MRFR) has thoroughly studied the trends and patterns governing the global electronic pills market over the forecast period of 2018-2023 in a detailed study. MRFR projects a CAGR of 15% within the electronic pills market over the forecast period.
Towering prevalence of gastrointestinal disorders has driven the market for electronic pills. Electronic pills alleviate tedious and painful diagnostic procedures such as colonoscopy and endoscopy and provide accurate results without much discomfort to the patient. Surging cases of stomach cancer coupled with increasing preference for minimally invasive medical procedures is likely to augment the growth of the electronic pills market. Healthcare professionals are increasingly adopting theses pills as they facilitate on-site diagnosis. Other factors which contribute to the growth of the market include improving reimbursement scenario and rise in global geriatric population who are more susceptible to various chronic diseases. Additionally, capsule endoscopy has gained widespread adoption as a non-invasive diagnostic method which is likely to fuel the growth of the market over the forecast period with new Electronic Pill Market Technology. On the contrary, the growth of the electronic pills market can be impeded by factors such as lack of awareness, capsule retention, and bowel obstruction. Moreover, high costs aligned with electronic pills and regulatory restrictions are anticipated to hinder the growth of the market.
Segmentation
The global electronic pill market has been segmented based on application, target area, part, and end user.
By application, the electronic pill market has been segmented into capsule endoscopy, drug delivery, and patient monitoring.
By target area, the electronic pill market has been segmented into oesophagus, stomach, small intestine, and large intestine.
By part, the electronic pill market has been segmented into biocompatible capsule encasing microsensors, control chip, radio transmitter and power source.
By end user, the electronic pill market has been segmented into Hospitals, diagnostic centers, clinical research organizations, and medical centers.
Regional Analysis
By region, the electronic pill market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
In 2017, the global electronic pill market was led by the Americas. The dominance of the Americas market can be attributed to the surging prevalence of gastrointestinal diseases, vigorous R&D activities and fast uptake of the latest technologies in the region.
Europe follows the Americas closely and is estimated to showcase substantial growth over the forecast period. Escalating cases of gastric cancer and high demand for diagnostics services is fuelling the growth of the market.
The APAC electronic market is likely to witness the fastest growth over the forecast period. The growth of the market can be attributed to increasing patient population, growing medical tourism in the region, and extensive R&D activities and high investment by the governments in the region create a conducive environment for the growth of the market.
The MEA market accounts for the least share of the electronic pill market. The growth of the market might be restrained by stringent government policies and poor economic conditions.
Competitive Landscape
Medtronic, JINSHAN Science & Technology, Medimetrics (Mexico), Medisafe, CapsoVision, Inc. (US), Given Imaging Ltd. (Israel), (Bio-Images Drug Delivery) BDD LTD (UK), Proteus Digital Health (US), Olympus Corporation, and INTROMEDIC are the distinguished players in the electronic pill market.
Industry Updates
February 2019 - a new electronic pill equipped with Wi-Fi transmitter has been developed which is capable of harvesting energy from inside a patient's stomach and record core body temperature and then send data to an external monitor.
Posted by at No comments:

Worldwide Immunofluorescence Assay Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2023

Market Scenario
The growing prevalence of chronic and infectious diseases increase in research and development activities, growing government investments for R&D activities, increased need for rapid and sensitive diagnostics, and adoption of technologically advanced systems are the key factors for the market to grow. However, factors such as, expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
The Global Immunofluorescence Assays Market Size is expected to reach an approximate CAGR of 5.8% during the forecast period.
According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease.  Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.
However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
Key Players
Some of the key players for the global Immunofluorescence Assay market are Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc.,BioTek Instruments,Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc. Becton Dickinson and Company , Merck , Agilent Technologies , TCS Biosciences Ltd, Maxvision Biosciences Inc. and Others.
Segmentation
The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique is sub segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and micro immunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method and double staining method. On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labelling dyes and species type. Instruments is further sub segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.
Regional Market Summary
The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.
It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.
The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. 
Posted by at No comments:

Chordoma Disease Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:

Venous Blood Collection Devices Market Staggering Double Digit Cagr Till 2023

Market Scenario
The Global Venous Blood Collection Devices Market is expected to expand at a CAGR of 9.3% over the forecast period of 2019-2023, reveals Market Research Future (MRFR) in a detailed study.
Venous blood collection devices are vessels used for collection, sampling, and testing blood samples. These devices are easy to handle, provide mechanical protection as well as protection from contamination and radiation. Moreover, these blood collection devices offer the exact filling volume.
The global venous blood collection devices market trends are driven by the increasing diagnostics and screening for numerous diseases, increasing health awareness leading to growing demand for blood collection devices for sampling, and with the growing preference for disposable products. Product development can be an attractive strategy for expanding the global venous blood collection devices market.
However, restraints that are likely to hinder the growth of the venous blood collection devices market include risks associated with contamination, pressure on prices, and low-quality products from unknown manufacturers. 
The global burden of chronic diseases is increasing at an alarming rate which induces high demand for screening services and consequently boosts the growth of the global venous blood collection devices market. This further complemented by growing disposable income and high health awareness among consumers. To meet the massive demands, medical device manufacturers are endeavoring towards product improvement which jhas resulted in teh devleopment of advanced venous blood collection devices that can be used for safer blood collection. Furthermore expansdion in product oportfolio by key medical device manufacturers have resulted in teh consolidation of teh global venous blood collection devices market. On the other hand, the growth of the market might be undermined by risks related to contamination, pricing pressure, and substandard product from local manufacturers.
Key Players
Some of the key players in the global venous blood collection devices market are Becton, Dickinson and Company (U.S), Bio-Rad Laboratories, Inc. (U.S), NIPRO Medical Corporation (Japan), Qiagen NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio One International GmbH (Greiner Group) (Austria), Terumo Medical Corporation (Japan), Sekisui Chemical Co., Ltd. (Japan), Sarstedt AG & Co (U.S.), F.L. Medical (Italy), Narang Medical (India), Soya Green Tec Co., Ltd. (South Korea), Biosigma (U.S.), Vital Diagnostice (ELITech Group) (U.S.), Improve Medical Technology Co. Ltd. (U.S.), Hongyu Medical (China), SanLI (Myanmar.), KHB (U.S.), Zhejiang Gongdong Medical Technology Co., Ltd. (China), CDRICH (China), Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark), Medtronic Plc (U.S.), Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.), Kabe Labortechnik GmbH (Germany), Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.
Segmentation
The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.
On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.
On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.
On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.
On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.
Regional Analysis                     
The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.
The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the venous blood collection devices market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas venous blood collection devices market.
The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.
Posted by at No comments:

Transgenic animals Market Expects An Extensive Growth In Roi Till 2023

Market Scenario:
Transgenic animals or genetically modified (GM) animals have a foreign gene inserted into their DNA structure for various applications such as production of drugs, resistance to disease, and increasing yields. For instance, GM cows, sheep, and goats can produce growth hormone, insulin, and anticoagulants. The global transgenic animals market report by Market Research Future (MRFR) contains a compilation of drivers, threats, and opportunities which can work well for interested investors.
In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
Key players For Transgenic Animals Market
  • Cyagen Biosciences,
  • Charles River,
  • Creative-Biolabs,
  • TRANS GENIC INC.., Ltd.,
  • Sutter Instrument Company,
  • Bio-Rad Laboratories, Inc.,
  • Spinco Biotech Pvt Ltd.,
  • Abbott,
  • Thermo Fisher Scientific Inc.,
  • Sigma-Aldrich Co.,
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others.
On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others.
On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
Browse Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/transgenic-animals-market-5464
Posted by at No comments:

Bone Biopsy Market Sparkling Growth Worldwide Forecasts By 2023

Market Scenario
The global bone biopsy market is expected to register ~4.5% CAGR during the forecast period of 2019 to 2025 and is expected to reach USD 718 million by 2025.
Bone biopsy is a procedure, in which a sample of cells or tissues are collected from the bone for examination. The procedure is generally performed to confirm the presence of bone cancer, investigation of a lesion, and identify the cause of inflammation or infection.
Furthermore, factors such as stringent regulatory policies, product recall, and others are hampering the growth of the market.

Segmentation
The global bone biopsy market is segmented on type, guidance, end users, and region.
The global market for bone biopsy, by type, is segmented into needle biopsy and open biopsy.
Based on guidance, the global market is divided into guided and non-guided, where the guided segment is further sub-segmented into MRI-guided and CT-guided. The guided segment is expected to hold the highest market share due to the clinical advantages over its non-guided counterparts.
The end user segment consists of hospitals & clinics, specialty centers, and others. The hospitals & clinics segment is expected to dominate the market due to the increasing number of hospitals.
In the current scope of the study, the segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The bone biopsy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European bone biopsy market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The bone biopsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bone biopsy market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players
Some of the key players operating in the global bone biopsy market are BD (US), B. Braun Melsungen AG (Germany), Cook (US), GENERAL ELECTRIC COMPANY (US), ARGON MEDICAL (US), MERMAID MEDICAL A/S (Denmark), Ranfac Corp. (US), Kimal (UK), and Remington Medical (US).

Regional Market Summary
 
The Americas dominated the bone biopsy market owing to the high prevalence of bone cancer and presence of major manufacturers in the region.
In 2018, Europe accounted for the second-largest market share. However, Asia-Pacific is expected to register the fastest CAGR due to increasing awareness regarding bone cancer and growing healthcare infrastructure. On the other hand, the Middle East & Africa is expected to hold the least share in the bone biopsy market due to limited access to health facilities and lack of awareness regarding health management.
Posted by at No comments:

Refsum Disease Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Scenario

Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Intended Audience
  • Pharmaceutical Companies
  • Hospitals & Clinics
  • Research and Development (R&D) Companies
  • Diagnostic Laboratories
  • Government Research Institute
  • Academic Institutes and Universities
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Regional Analysis
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Posted by at No comments:
Subscribe to: Posts (Atom)